ES2528363T3 - Tratamiento para el cáncer - Google Patents
Tratamiento para el cáncer Download PDFInfo
- Publication number
- ES2528363T3 ES2528363T3 ES05813351.3T ES05813351T ES2528363T3 ES 2528363 T3 ES2528363 T3 ES 2528363T3 ES 05813351 T ES05813351 T ES 05813351T ES 2528363 T3 ES2528363 T3 ES 2528363T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- unsubstituted
- alkenylalkyl
- cycloalkenylalkyl
- cycloalkylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Al menos un taxoide en una cantidad efectiva y al menos un compuesto carbamato de benzimidazol de fórmula I:**Fórmula** en la que R1 se selecciona de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, -SR7, -SOR8, -SO2R9, -SCN, B'(CH2)nBR10, -C(O)-R11 o -OR12, COOR13, -NO2, NR13aCOOR13b, isotiocianato o -CN donde R7 a R13b se seleccionan cada uno independientemente de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, B y B' se seleccionan independientemente de O, S, S(O) o SO2 y n es de 1 a 4; R2 se selecciona de H o alquilo sustituido o no sustituido; R3 se selecciona de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo, arilalquilo, anillo heterocíclico de 5 o 6 miembros, cuyo(s) heteroátomo(s) se selecciona(n) de uno o más de O, S y/o N, -SR14, -OR15, -SOR16, -SO2R17, -SCN, -C(O)-R18, - OR19, NR20COOR21, en donde R15 a R21 cada uno se selecciona independientemente de H, alquilo sustituido o no sustituido, de cadena lineal o ramificada, alquenilo, alquenilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilalquilo, arilo o arilalquilo; en una cantidad efectiva para su uso en el tratamiento de un tumor de ovario en un sujeto.
Description
Claims (1)
-
imagen1 imagen2 imagen3
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004906983 | 2004-12-06 | ||
AU2004906983A AU2004906983A0 (en) | 2004-12-06 | Treatment for cancer | |
PCT/AU2005/001839 WO2006060853A1 (en) | 2004-12-06 | 2005-12-06 | Treatment for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2528363T3 true ES2528363T3 (es) | 2015-02-09 |
Family
ID=36577596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES05813351.3T Active ES2528363T3 (es) | 2004-12-06 | 2005-12-06 | Tratamiento para el cáncer |
Country Status (9)
Country | Link |
---|---|
US (2) | US20090286838A1 (es) |
EP (1) | EP1830847B1 (es) |
JP (1) | JP2008522984A (es) |
KR (1) | KR101287917B1 (es) |
CN (1) | CN101111248A (es) |
CA (1) | CA2589828C (es) |
ES (1) | ES2528363T3 (es) |
PT (1) | PT1830847E (es) |
WO (1) | WO2006060853A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009043093A1 (en) * | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
KR20090046142A (ko) | 2007-11-05 | 2009-05-11 | 삼성전자주식회사 | 입력 필체 자동 변환 시스템 및 방법 |
EP2251010A1 (en) | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
US20120064008A1 (en) * | 2009-05-20 | 2012-03-15 | Bruce Zetter | Compositions for the treatment of metastatic cancer and methods of use thereof |
US20120202840A1 (en) * | 2009-10-09 | 2012-08-09 | University Health Network | Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2014022879A1 (en) * | 2012-08-06 | 2014-02-13 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mtor pathway related diseases |
CN103054858A (zh) * | 2013-01-21 | 2013-04-24 | 杭州雷索药业有限公司 | 奥苯达唑在制备抗血管生成类药物中的应用 |
US9833431B2 (en) * | 2013-11-01 | 2017-12-05 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
JP2022553298A (ja) * | 2019-10-21 | 2022-12-22 | アキュラ ナノメディスン コーポレーション | 癌を処置する方法 |
CN111388469B (zh) * | 2019-10-21 | 2021-11-02 | 温州医科大学 | 一种芬苯达唑在制备抗肿瘤药物中的应用 |
KR102516896B1 (ko) * | 2020-10-19 | 2023-04-03 | 고려대학교 산학협력단 | 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
CN113648308A (zh) * | 2021-09-14 | 2021-11-16 | 东莞市人民医院 | 奥芬达唑作为抗卵巢癌药物的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5900429A (en) * | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
PE11499A1 (es) * | 1997-05-16 | 1999-03-01 | Procter & Gamble | Tratamiento del hiv y cancer |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
GB9900752D0 (en) * | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
US6423734B1 (en) * | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
AU2001257325A1 (en) * | 2000-04-28 | 2001-11-12 | The Procter And Gamble Company | Cancer treatment |
WO2002067932A1 (en) * | 2001-01-11 | 2002-09-06 | Board Of Regents, The University Of Texas System | Antihelminthic drugs as a treatment for hyperproliferative diseases |
US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
EP1379242B1 (en) * | 2001-03-26 | 2012-08-15 | Newsouth Innovations Pty Limited | Method for treatment of cancer and compositions for use therein |
EP1529044B1 (en) * | 2002-08-02 | 2007-10-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
-
2005
- 2005-12-06 EP EP05813351.3A patent/EP1830847B1/en not_active Not-in-force
- 2005-12-06 CN CNA2005800474469A patent/CN101111248A/zh active Pending
- 2005-12-06 KR KR1020077015596A patent/KR101287917B1/ko not_active IP Right Cessation
- 2005-12-06 JP JP2007544694A patent/JP2008522984A/ja active Pending
- 2005-12-06 CA CA2589828A patent/CA2589828C/en not_active Expired - Fee Related
- 2005-12-06 WO PCT/AU2005/001839 patent/WO2006060853A1/en active Application Filing
- 2005-12-06 PT PT58133513T patent/PT1830847E/pt unknown
- 2005-12-06 US US11/720,884 patent/US20090286838A1/en not_active Abandoned
- 2005-12-06 ES ES05813351.3T patent/ES2528363T3/es active Active
-
2012
- 2012-04-27 US US13/457,860 patent/US8835478B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101111248A (zh) | 2008-01-23 |
EP1830847A4 (en) | 2012-09-12 |
CA2589828C (en) | 2014-07-08 |
US20090286838A1 (en) | 2009-11-19 |
CA2589828A1 (en) | 2006-06-15 |
US8835478B2 (en) | 2014-09-16 |
WO2006060853A1 (en) | 2006-06-15 |
EP1830847A1 (en) | 2007-09-12 |
US20120214856A1 (en) | 2012-08-23 |
EP1830847B1 (en) | 2014-11-19 |
KR20070112113A (ko) | 2007-11-22 |
PT1830847E (pt) | 2015-02-05 |
KR101287917B1 (ko) | 2013-07-23 |
JP2008522984A (ja) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2528363T3 (es) | Tratamiento para el cáncer | |
RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
RU2485104C2 (ru) | Новые производные 1,2-дигидрохинолина, обладающие активностью связывания глюкокортикоидного рецептора | |
RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
RU2008144805A (ru) | Применение биарилкарбоксамидов в лечении заболеваний, связанных с hedgehog-путем | |
AR054799A1 (es) | Derivados de oxindol | |
RU2001121138A (ru) | Ингибиторы тромбина | |
RU2007137133A (ru) | Новый ингибитор hsp90 | |
RU2011108563A (ru) | Способы лечения талассемии | |
PE20040165A1 (es) | Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular | |
KR930005985A (ko) | Hiv 역전사효소의 억제제 | |
PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
RU2004117545A (ru) | Аминопиримидины и пиридины | |
BR112022001931A2 (pt) | Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer | |
RU2008108984A (ru) | Терапевтический агент от диабета | |
PE20070135A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
JP2006508030A5 (es) | ||
PE20020585A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
AR048361A1 (es) | Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos | |
PE20010932A1 (es) | N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida inhibidores de cinasas dependientes de ciclina | |
PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
EA200800924A1 (ru) | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера | |
EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |